[1]
von Eckardstein A, Widmann C. HDLs and beta cells. Cardiovasc Res 2014; 103(3): 384-94.
[2]
Tan CE, Chew LS, Chio LF, et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract 2001; 51(2): 107-14.
[3]
Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and metaregression analysis. BMJ 2009; 338: b92.
[4]
Vergès B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31(5): 429-39.
[5]
Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17(10): 594-603.
[6]
Dullaart RP, Otvos JD, James RW. Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects. Clin Biochem 2014; 47(12): 1022-7.
[7]
Perségol L, Vergès B, Foissac M, Gambert P, Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2006; 49(6): 1380-6.
[8]
Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: The atherosclerosis risk in communities study. Diabetes Care 2005; 28: 2013-8.
[9]
Wilson PF, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: The framingham offspring study. Arch Intern Med 2007; 167: 1068-74.
[10]
Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103-11.
[11]
Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab 2011; 22: 9-15.
[12]
Haase CL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. High-density lipoprotein cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes 2015; 64: 3328-33.
[13]
Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237-45.
[14]
Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodium glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 2014; 25: 2028-39.
[15]
Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol 2017; 312(5): F819-35.
[16]
Ichikawa R, Daimon M, Miyazaki T, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 2013; 12: 38.
[17]
Matshela MR. Second in a series on diabetes and the heart: diabetic cardiomyopathy - mechanisms and mode of diagnosis. E-Journal of Cardiology Practice 2016; 14(15)
[18]
Pinto TE, Gusso S, Hofman PL, et al. Systolic and Diastolic Abnormalities Reduce the Cardiac Response to Exercise in Adolescents with Type 2 Diabetes. Diabetes Care 2014; 37(5): 1439-46.
[19]
Ernande L, Rietzschel ER, Bergerot C, et al. Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. J Am Soc Echocardiogr 2010; 23: 1266-72.
[20]
Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003; 41: 611-7.
[21]
Freire CM, Moura AL, Barbosa Mde M, Machado LJ, Nogueira AI, Ribeiro-Oliveira Jr A. Left ventricle diastolic dysfunction in diabetes: an update. Arq Bras Endocrinol Metabol 2007; 51(2): 168-75.
[22]
Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42: 328-35.
[23]
Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med 2012; 29: 453-63.
[24]
Hammer S, van der Meer RW, Lamb HJ, et al. Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008; 295: E714-8.
[25]
O’Neill BT, Abel ED. Akt1 in the cardiovascular system: friend or foe? J Clin Invest 2005; 115: 2059-64.
[26]
Westermann D, Walther T, Savvatis K, et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 2009; 58: 1373-81.
[27]
Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K, Anders HJ. Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol 2010; 176: 1079-83.
[28]
Kadappu KK, Boyd A, Eshoo S, et al. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? Eur Heart J Cardiovasc Imaging 2012; 13(12): 1016-23.
[29]
Li B, Pan Y, Li X. Type 2 Diabetes Induces Prolonged P-wave Duration without Left Atrial Enlargement. J Korean Med Sci 2016; 31(4): 525-34.
[30]
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001; 286(3): 327-34.
[31]
Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health study. Diabetes 2001; 50(10): 2384-9.
[32]
Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland Coronary Prevention Study. Diabetes 2002; 51(5): 1596-600.
[33]
Festa A, D’Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51(4): 1131-7.
[34]
Paulmichl K, Hatunic M, Højlund K, et al. Modification and Validation of the Triglyceride-to-HDL Cholesterol Ratio as a Surrogate of Insulin Sensitivity in White Juveniles and Adults without Diabetes Mellitus: The Single Point Insulin Sensitivity Estimator (SPISE). Clin Chem 2016; 62(9): 1211-9.
[35]
Iwani NA, Jalaludin MY, Zin RM, et al. Triglyceride to HDL-C Ratio is Associated with Insulin Resistance in Overweight and Obese Children. Sci Rep 2017; 7: 40055.
[36]
Giannini C, Santoro N, Caprio S, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diab Care 2011; 34: 1869-74.
[37]
Gluba-Brzózka A, Franczyk B, Banach M, Rysz-Górzyńska M. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol 2017; 49(1): 155-64.
[38]
Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN. Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta 2002; 317(1-2): 119-23.
[39]
Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 2013; 124(2): 116-25.
[40]
Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010; 21(4): 312-8.
[42]
Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis 2017; 16(1): 207.
[43]
Cartolano FC, Dias GD, de Freitas MCP, Figueiredo Neto AM, Damasceno NRT. Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects. J Diabetes Res 2017. 1018796
[44]
Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52(2): 453-62.
[45]
MacLean PS, Vadlamudi S, MacDonald KG, Pories WJ, Houmard JA, Barakat HA. Impact of insulin resistance on lipoprotein subpopulation distribution in lean and morbidly obese nondiabetic women. Metabolism 2000; 49(3): 285-92.
[46]
Zhao X, Zhang HW, Zhang Y, et al. Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. Heart Lung Circ 2017; 26(3): 211-8.
[47]
Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis. Diabetes Care 2015; 38(4): 628-36.
[48]
Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010; 51(6): 1546-53.
[49]
Tamehiro N, Shigemoto-Mogami Y, Kakeya T, et al. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter 1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007; 282: 21090-9.
[50]
Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002; 43(10): 1701-7.
[51]
Li JJ, Zhang Y, Li S, et al. Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study. Medicine (Baltimore) 2016; 95(4) e2600
10